1. Home
  2. DIN vs FULC Comparison

DIN vs FULC Comparison

Compare DIN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DIN

Dine Brands Global Inc.

HOLD

Current Price

$35.23

Market Cap

399.8M

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.84

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DIN
FULC
Founded
1958
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
399.8M
467.8M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
DIN
FULC
Price
$35.23
$3.84
Analyst Decision
Hold
Buy
Analyst Count
7
8
Target Price
$29.00
$16.38
AVG Volume (30 Days)
358.1K
3.4M
Earning Date
05-06-2026
04-27-2026
Dividend Yield
2.78%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
$879,300,000.00
N/A
Revenue This Year
$3.61
N/A
Revenue Next Year
$0.64
N/A
P/E Ratio
$62.54
N/A
Revenue Growth
8.25
N/A
52 Week Low
$19.58
$2.83
52 Week High
$39.68
$15.74

Technical Indicators

Market Signals
Indicator
DIN
FULC
Relative Strength Index (RSI) 59.62 41.39
Support Level $33.47 $2.83
Resistance Level $36.06 $4.02
Average True Range (ATR) 1.49 0.23
MACD 0.03 0.14
Stochastic Oscillator 66.21 70.09

Price Performance

Historical Comparison
DIN
FULC

About DIN Dine Brands Global Inc.

Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: